Evolus (EOLS) Cash from Investing Activities (2018 - 2026)
Evolus (EOLS) posted Cash from Investing Activities of -$1.7 million for Q1 2026, up 21.93% on a QoQ basis from -$2.2 million in Q4 2025, and up 9.13% year-over-year from -$1.5 million in Q1 2025.
Evolus (EOLS) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Evolus' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$1.7 million for Q1 2026.
- Quarterly Cash from Investing Activities rose 9.13% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.3 million (down 40.68% YoY) and the FY2025 annual result came in at -$8.5 million, down 75.24% from the prior year.
- Cash from Investing Activities was -$1.7 million for Q1 2026 at Evolus, up from -$2.2 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$216000.0 in Q2 2023 and bottomed at -$2.3 million in Q2 2025.
- A 5-year average of -$1.1 million and a median of -$1.3 million in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 4380.95% — and 2023, when it soared 74.05%.
- Evolus' Cash from Investing Activities stood at -$1.4 million in 2022, then surged by 74.05% to -$361000.0 in 2023, then tumbled by 277.29% to -$1.4 million in 2024, then plunged by 59.03% to -$2.2 million in 2025, then grew by 21.93% to -$1.7 million in 2026.
- Business Quant data shows EOLS's Cash from Investing Activities at -$1.7 million in Q1 2026, -$2.2 million in Q4 2025, and -$2.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.84 Bn | 32.10 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.12 Bn | 20.96 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Evolus | 401.22 Mn | 351.43 Mn | 48.90 Mn | -1.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.69 Mn |
| Mar 31, 2026 | -1.69 Mn |
| Dec 31, 2025 | -2.17 Mn |
| Dec 31, 2025 | -2.17 Mn |
| Sep 30, 2025 | -2.16 Mn |
| Sep 30, 2025 | -2.16 Mn |
| Jun 30, 2025 | -2.27 Mn |
| Jun 30, 2025 | -2.27 Mn |
| Mar 31, 2025 | -1.86 Mn |
| Mar 31, 2025 | -1.86 Mn |
| Dec 31, 2024 | -1.36 Mn |
| Dec 31, 2024 | -1.36 Mn |
| Sep 30, 2024 | -1.41 Mn |
| Sep 30, 2024 | -1.41 Mn |
| Jun 30, 2024 | -1.25 Mn |
| Jun 30, 2024 | -1.25 Mn |
| Mar 31, 2024 | -797,000.00 |
| Mar 31, 2024 | -797,000.00 |
| Dec 31, 2023 | -361,000.00 |
| Dec 31, 2023 | -361,000.00 |